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Point-of-care tests for STIs: the 
way forward
Igor Toskin,1 Rosanna W Peeling,2 David Mabey,3 King Holmes,4 
Ronald Ballard,1 James Kiarie,1 Ian Askew1
It has been over 10 years since the WHO 
Sexually Transmitted Diseases Diagnostics 
Initiative (SDI) published a full supple-
ment in this journal on rapid diagnostic 
testing for STIs,1 making the case for qual-
ity-assured rapid STI tests to help coun-
tries achieve their Millennium 
Development Goals and decrease the 
STI burden worldwide. The supplement 
introduced the ASSURED criteria to assess 
whether diagnostics were appropriate for 
disease control needs, namely: Affordable, 
Sensitive, Specific, User-friendly, Rapid 
and robust, Equipment-free and Deliver-
able to end users.2 This ASSURED 
approach has broadened the paradigm of 
STI testing from rapid to point-of-care 
testing (POCT) or near-patient testing. 
Testing and delivering the results rapidly 
and conveniently to the patient will 
increase the likelihood of appropriate and 
immediate treatment and decrease the 
chances of onward transmission and 
development of reproductive sequelae.
The most recent WHO estimates found 
that in 2012, among people aged 15–49 
years, there were an estimated 6 million 
new cases of syphilis each year, 78 million 
cases of gonorrhoea, 131 million cases 
of chlamydial infection and 142 million 
cases of trichomoniasis—the four most 
common curable STIs.3 A separate liter-
ature review, including a modelling anal-
ysis, suggested that in 2012, 417 million 
people 15–49 years of age were living 
with herpes simplex virus type 2 infec-
tion worldwide,4 and 291 million women 
with genital human papillomavirus (HPV) 
infection.5 These pandemics, and the 
growing number of STIs caused by other 
pathogens have a profound impact on the 
health and lives of children, adolescents 
and adults worldwide.6
To achieve a sustainable decrease of STI 
infections globally, the new WHO STI 
health sector strategy reaffirms the need 
for early diagnosis of STIs, screening for 
asymptomatic carriers of infection and 
linkage to treatment, as a core interven-
tion.6 The strategy nevertheless acknowl-
edges the lack of reliable, low-cost POCTs 
as a major barrier to advancing STI 
control and prevention, and lists the vali-
dation and standardisation of innovative 
diagnostic technologies and approaches as 
one of the key priorities.
Since the supplement on rapid tests for 
STIs in 2006, considerable progress has 
been made in POCT technology, concep-
tualisation, evaluation and implementa-
tion, but this has not yet been translated 
into global uptake of POCTs as one of the 
essential interventions included in public 
health strategies. Therefore, the WHO 
Department of Reproductive Health and 
Research convened two technical consul-
tations, in 2014 and 2015, with experts 
from all regions, to discuss the state of 
affairs in the POCT field, defining the 
gaps and the way forward. The current 
supplement offers insight into the evolu-
tion of POCT in the last 10 years and the 
plans for the future.
The first article in this supplement 
gives an overview of target product 
profiles, as defined during the expert 
consultation, against which the currently 
available POCTs can be assessed, and 
should help to guide the development 
and validation of new STI POCTs. It also 
includes a summary of the current tech-
nologies and tests on the market for the 
four major curable STIs, and for HPV, as 
well as POCTs that are in the pipeline. 
In the 2006 supplement, several papers 
described performance characteristics of 
simple lateral flow devices. During the 10 
years following its publication, research 
groups have developed more sophisti-
cated technologies, some based on molec-
ular testing. Looking forward, progress 
in microfluidics and nanotechnology will 
hopefully allow for multiplex POC plat-
forms and enable quantitative analyses.7
POCTs are promising tools to combat 
the increasing threat of antimicrobial 
resistance (AMR) in both STI pathogens 
and other microorganisms.8 In this 
supplement, new POCT technologies 
are discussed that enable AMR sensitive 
diagnosis. This will drastically reduce 
inappropriate prescribing and dispensing 
of antibiotics, which is indispensable for 
global strategies to control the spread and 
impact of AMR.9
POCTs may have excellent performance 
characteristics in a laboratory environ-
ment, but their usefulness, their perfor-
mance and operational characteristics, 
should be assessed in clinical settings and 
in the field. This supplement includes 
systematic reviews that synthesise the 
results of field evaluations of POCTs for 
chlamydial infection, gonorrhoea, tricho-
moniasis and HPV infection; and also 
summarises performance of dual HIV/
syphilis POCTs in different patient groups 
and clinical settings.
POCTs should increasingly become the 
diagnostics of the future, particularly in 
low and middle-income countries, both in 
primary care centres and outreach settings, 
enabling patient-centred STI testing 
and treatment in key populations.10 11 
However, our systematic reviews showed 
that we need improvements in the sensi-
tivity of antigen detection lateral flow 
assays and more affordable (near) POC 
molecular assays before necessary guide-
lines and recommendations can be made 
on the use of POCTs in low resource 
settings, both for screening programmes 
for detection of asymptomatic infections 
and to complement syndromic manage-
ment algorithms in order to guide better 
clinical decisions and follow-up. The 
potential impact of POCTs in regions 
where syndromic management is the stan-
dard of care cannot be overemphasised.
The potential use of syphilis POCTs in 
reaching vulnerable populations such as 
the indigenous population in the Brazilian 
Amazon, is an important element of the 
global control strategy.6 Our supplement 
offers an example on the programmatic 
potential of POCTs in reducing the burden 
of syphilis in men who have sex with men 
in Italy.
The introduction of POC CD4 
enumeration technologies has shown 
that managing a national network of 
POC sites can be challenging in some 
contexts.12 Decentralised testing requires 
major commitments to training and moni-
toring of effectiveness, while ensuring 
quality test results and avoiding operator 
and instrument errors, instrument break-
downs, and stock-outs of reagents or other 
supplies. Technological innovation alone 
will thus not be sufficient. Decentralisa-
tion of testing could be seen as a concern 
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by laboratories, as some of their tasks 
regarding STI testing, might be dimin-
ished. Our international expert group 
suggested anticipating these tensions by 
assessing the capability and willingness of 
laboratories to take up their new role, that 
is, to provide training, quality assurance, 
and monitor and evaluate STI testing, 
during and after the shift to POCTs. The 
laboratory will become both a command 
and training centre for POCTs and its 
providers and a centre of quality assurance 
and certification.13
During the technical consultations, 
experts did point to the knowledge gaps in 
basic research and development of POCTs, 
and discussed their evaluation and poten-
tial programmatic impact. Suggestions to 
advance the field of POCTs are presented 
in the last article of the supplement. The 
‘roadmap’ elaborates more on decen-
tralised testing and the new important 
role of reference laboratories, the surveil-
lance potential of using connectivity 
technologies, self-testing, and the need 
for an investment case. It also reflects on 
the assessment of the needs of and feed-
back14 from end users, both patients and 
healthcare providers, which are crucial for 
successful roll-out of POCTs. This is espe-
cially important for diagnostic tools which 
can be used as self-tests.
If implemented sensibly, POCTs can be 
catalysts for health systems strengthening 
globally.14 15 The health sector response 
to STI epidemics is critical to the achieve-
ment of universal health coverage—one of 
the key targets of the Sustainable Develop-
ment Goals. POCT could in the long run 
replace non-specific syndromic manage-
ment of STIs with specific recommended 
treatments for proven infections. POCTs 
also have the potential of expanding 
targeted STI screening and rapidly linking 
the nfected patients to treatment. This 
may decrease STI incidence, and conse-
quent morbidity and mortality, improving 
the sexual health and well-being of all 
people.
Contributors All authors defined the concept and 
content of the editorial, IT wrote the manuscript; all 
authors reviewed, edited and approved the editorial.
Disclaimer The authors are staff members of the 
World Health Organization. The authors alone are 
responsible for the views expressed in this publication 
and they do not necessarily represent the views, 
decisions or policies of the World Health Organization.
Competing interests None declared.
Provenance and peer review Commissioned; 
externally peer reviewed.
© World Health Organization 2017. Licensee BMJ 
Publishing Group Limited. This is an open access article 
distributed under the terms of the Creative Commons 
Attribution IGO License (https:// creativecommons. org/ 
licenses/ by/ 4. 0/ igo), which permits use, distribution, 
and reproduction for non-commercial purposes in any 
medium, provided the original work is properly cited. In 
any reproduction of this article there should not be any 
suggestion that WHO or this article endorse any specific 
organization or products. The use of the WHO logo is 
not permitted. This notice should be preserved along 
with the article’s original URL.
To cite Toskin I, Peeling RW, Mabey D, et al. 
Sex Transm Infect 2017;93:S1–S2.
Received 3 April 2017
Revised 21 June 2017
Accepted 2 July 2017
Sex Transm Infect 2017;93:S1–S2.
doi:10.1136/sextrans-2016-053074
REfEREncEs
 1 Peeling RW, Holmes KK, Mabey D, et al. Rapid tests for 
sexually transmitted infections (STIs): the way forward. 
Sex Transm Infect 2006;82(Suppl V):v1–6.
 2 Peeling RW, Mabey D, Herring A, et al. Why do 
we need quality-assured diagnostic tests for 
sexually transmitted infections? Nat Rev Microbiol 
2006;4:909–21.
 3 Newman L, Rowley J, Vander Hoorn S, et al. Global 
estimates of the prevalence and incidence of four 
curable sexually transmitted infections in 2012 based 
on systematic review and global reporting. PLoS One 
2015;10:e0143304.
 4 Looker KJ, Magaret AS, Turner KM, et al. Global 
estimates of prevalent and incident herpes 
simplex virus type 2 infections in 2012. PLoS One 
2015;10:e114989.
 5 de Sanjosé S, Diaz M, Castellsagué X, et al. 
Worldwide prevalence and genotype distribution of 
cervical human papillomavirus DNA in women with 
normal cytology: a meta-analysis. Lancet Infect Dis 
2007;7:453–9.
 6 World Health Organization. Global health sector 
strategy on sexually transmitted infections, 
2016–2021. Geneva: WHO, 2016. http://www. who. 
int/ reproductivehealth/ publications/ rtis/ ghss- stis/ en/.
 7 Damhorst GL, Murtagh M, Rodriguez WR, et al. 
Microfluidics and nanotechnology for detection of 
global infectious diseases. Proc IEEE Inst Electr Electron 
Eng 2015;103:150–60.
 8 World Health Organization. Global action plan on 
antimicrobial resistance. Geneva: WHO, 2015. http://
www. who. int/ antimicrobial- resistance/ publications/ 
global- action- plan/ en/
 9 World Health Organization. Global action plan to 
control the spread and impact of antimicrobial 
resistance in Neisseria gonnorrhoeae. Geneva: WHO, 
2012. http://www. who. int/ reproductivehealth/ 
publications/ rtis/ 9789241503501/ en/
 10 World Health Organization. Report on global sexually 
transmitted infection surveillance 2013. Geneva: 
WHO, 2014. http://www. who. int/ reproductivehealth/ 
publications/ rtis/ stis- surveillance- 2013/ en/
 11 Garcia PJ, You P, Fridley G, et al. Point-of-care 
diagnostic tests for low-resource settings. Lancet Glob 
Health 2015;3:e257–8.
 12 Nkengasong J, Boeras DI, Abimiku Alash’le, et al. 
Assuring the quality of diagnostic testing: The future is 
now. Afr J Lab Med 2016;5:a558.
 13 Boeras DI, Nkengasong JN, Peeling RW. 
Implementation science: the laboratory as a command 
centre. Curr Opin HIV AIDS 2017;12:171–4.
 14 Mabey DC, Sollis KA, Kelly HA, et al. Point-of-care  
tests to strengthen health systems and save  
newborn lives: the case of syphilis. PLoS Med  
2012;9:e1001233.
 15 García PJ, Cárcamo CP, Chiappe M, et al. Rapid syphilis 
tests as catalysts for health systems strengthening: a 
case study from Peru. PLoS One 2013;8:e66905.
group.bmj.com on January 4, 2018 - Published by http://sti.bmj.com/Downloaded from 
Point-of-care tests for STIs: the way forward
Ballard, James Kiarie and Ian Askew
Igor Toskin, Rosanna W Peeling, David Mabey, King Holmes, Ronald
doi: 10.1136/sextrans-2016-053074
2017 93: S1-S2 Sex Transm Infect 
 http://sti.bmj.com/content/93/S4/S1
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://sti.bmj.com/content/93/S4/S1
This article cites 9 articles, 1 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (266)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 4, 2018 - Published by http://sti.bmj.com/Downloaded from 
